INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 112 filers reported holding INTELLIA THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is 0.73 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,534,248 | -17.6% | 80,147 | +6.3% | 0.00% | 0.0% |
Q2 2023 | $3,074,608 | +11.3% | 75,395 | +1.7% | 0.00% | 0.0% |
Q1 2023 | $2,762,303 | +9.3% | 74,116 | +2.3% | 0.00% | 0.0% |
Q4 2022 | $2,526,630 | -34.1% | 72,417 | +5.7% | 0.00% | 0.0% |
Q3 2022 | $3,834,000 | +2.1% | 68,524 | -5.6% | 0.00% | 0.0% |
Q2 2022 | $3,756,000 | -23.4% | 72,556 | +7.6% | 0.00% | 0.0% |
Q1 2022 | $4,902,000 | -36.2% | 67,451 | +3.9% | 0.00% | -50.0% |
Q4 2021 | $7,680,000 | +0.4% | 64,948 | +13.9% | 0.00% | 0.0% |
Q3 2021 | $7,649,000 | +11.3% | 57,018 | +34.3% | 0.00% | 0.0% |
Q2 2021 | $6,873,000 | +128.6% | 42,449 | +13.4% | 0.00% | +100.0% |
Q1 2021 | $3,006,000 | -15.5% | 37,447 | -42.8% | 0.00% | 0.0% |
Q4 2020 | $3,558,000 | +91.3% | 65,416 | -30.1% | 0.00% | 0.0% |
Q3 2020 | $1,860,000 | +51.2% | 93,549 | +59.8% | 0.00% | 0.0% |
Q2 2020 | $1,230,000 | +330.1% | 58,529 | +184.8% | 0.00% | – |
Q1 2020 | $286,000 | +70.2% | 20,554 | +79.1% | 0.00% | – |
Q4 2019 | $168,000 | +28.2% | 11,476 | +13.1% | 0.00% | – |
Q3 2019 | $131,000 | +8.3% | 10,150 | +28.4% | 0.00% | – |
Q2 2019 | $121,000 | +21.0% | 7,907 | +34.8% | 0.00% | – |
Q1 2019 | $100,000 | +25.0% | 5,864 | 0.0% | 0.00% | – |
Q4 2018 | $80,000 | -48.7% | 5,864 | +8.1% | 0.00% | – |
Q3 2018 | $156,000 | +4.7% | 5,427 | 0.0% | 0.00% | – |
Q2 2018 | $149,000 | +129.2% | 5,427 | +75.4% | 0.00% | – |
Q1 2018 | $65,000 | -25.3% | 3,094 | -30.9% | 0.00% | – |
Q4 2017 | $87,000 | -16.3% | 4,479 | +5.9% | 0.00% | – |
Q3 2017 | $104,000 | +79.3% | 4,231 | +16.5% | 0.00% | – |
Q2 2017 | $58,000 | +75.8% | 3,632 | +51.9% | 0.00% | – |
Q1 2017 | $33,000 | +13.8% | 2,391 | +8.6% | 0.00% | – |
Q4 2016 | $29,000 | +11.5% | 2,201 | +41.0% | 0.00% | – |
Q3 2016 | $26,000 | -25.7% | 1,561 | 0.0% | 0.00% | – |
Q2 2016 | $35,000 | – | 1,561 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 744,160 | $54,078,000 | 5.79% |
Discovery Value Fund | 986,173 | $71,665,000 | 5.28% |
Ally Bridge Group (NY) LLC | 60,000 | $4,360,000 | 3.23% |
MPM BioImpact LLC | 159,409 | $11,584,000 | 3.11% |
ARK Investment Management | 8,981,029 | $652,651,000 | 2.72% |
Elmwood Wealth Management, Inc. | 67,599 | $4,912,000 | 2.52% |
Nikko Asset Management Americas, Inc. | 2,872,269 | $192,442,000 | 1.41% |
Frazier Life Sciences Management, L.P. | 203,684 | $14,802,000 | 1.26% |
REGENTS OF THE UNIVERSITY OF CALIFORNIA | 111,440 | $8,098,000 | 1.22% |
Merlin Capital, Inc | 11,575 | $841,000 | 1.11% |